Healthinvest Partners Ab buys $21,410,312 stake in AMAG Pharmaceuticals (AMAG)

AMAG Pharmaceuticals (AMAG) : Healthinvest Partners Ab scooped up 220,585 additional shares in AMAG Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 19, 2016. The investment management firm now holds a total of 740,585 shares of AMAG Pharmaceuticals which is valued at $21,410,312.AMAG Pharmaceuticals makes up approximately 9.07% of Healthinvest Partners Ab’s portfolio.

AMAG Pharmaceuticals opened for trading at $27.83 and hit $28.98 on the upside on Friday, eventually ending the session at $28.91, with a gain of 3.73% or 1.04 points. The heightened volatility saw the trading volume jump to 12,46,874 shares. Company has a market cap of $1,005 M.

Other Hedge Funds, Including , New York State Teachers Retirement System added AMAG to its portfolio by purchasing 14,225 company shares during the most recent quarter which is valued at $411,245.Simplex Trading boosted its stake in AMAG in the latest quarter, The investment management firm added 4,839 additional shares and now holds a total of 10,718 shares of AMAG Pharmaceuticals which is valued at $272,773. AMAG Pharmaceuticals makes up approx 0.04% of Simplex Trading’s portfolio. Capstone Asset Management Co added AMAG to its portfolio by purchasing 10,346 company shares during the most recent quarter which is valued at $263,306. AMAG Pharmaceuticals makes up approx 0.01% of Capstone Asset Management Co’s portfolio.Creative Planning reduced its stake in AMAG by selling 11 shares or 2.68% in the most recent quarter. The Hedge Fund company now holds 400 shares of AMAG which is valued at $9,832.

On the company’s financial health, AMAG Pharmaceuticals reported $1.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on Feb 17, 2016. Analyst had a consensus of $1.16. The company had revenue of $108.70 million for the quarter, compared to analysts expectations of $116.67 million. The company’s revenue was up 103.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.67 EPS.

Many Wall Street Analysts have commented on AMAG Pharmaceuticals. Barclays Initiated AMAG Pharmaceuticals on Jan 21, 2016 to “Equal Weight”, Price Target of the shares are set at $32.

AMAG Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on maternal health anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection) Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers such as those caused by oral surgery or ill-fitting dentures or braces.

Leave a Reply

AMAG Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on AMAG Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.